VEGFA and age-related macular degeneration: Curtis et al. used Medicare claims data to show that anti-VEGF use for AMD increased dramatically from 2006–2008, which paralleled an increase in office visits and a decrease in photodynamic therapy and thermal laser treatments.[8] Yet, concerns arose when later studies observed a high rate of anti-VEGF discontinuation, and also showed that even those who stayed on therapy received a lower frequency of injections than the monthly protocol thought to have optimal outcomes as demonstrated by major AMD randomized clinical trials.[9–11]